Results 131 to 140 of about 5,026 (198)

Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort study. [PDF]

J Neurol
Oeztuerk M, Huntemann N, Gerischer L, Herdick M, Nelke C, Stascheit F, Hoffmann S, Lehnerer S, Stein M, Schubert C, Schneider-Gold C, Pfeuffer S, Krämer HH, Konen FF, Skripuletz T, Pawlitzki M, Rehmann R, Arat E, Menskes CB, Glaubitz S, Zschüntzsch J, Scherwietes V, Totzeck A, Hagenacker T, Meisel A, Meuth SG, Ruck T.   +26 more
europepmc   +1 more source

Biomimetic nanovesicles decorated with chemotactic and target membrane proteins for lupus nephritis treatment. [PDF]

J Nanobiotechnology
Gan J, Huang D, Liu R, Zhao Y, Sun L.
europepmc   +1 more source

Transplacental Antibody Transfer: Mechanisms, Pregnancy-Related Disruptions, and Emerging Experimental Models. [PDF]

Antibodies (Basel)
Li Q, Huang Z, Saeed Z, Greer O, Harker JA, Shah NM.   +5 more
europepmc   +1 more source

Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review. [PDF]

Neurol Int
Takahashi S, Kinno R.
europepmc   +1 more source

From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases. [PDF]

Front Immunol
Yang CW, Xia T, Tan Q, Jie LG, Lou AJ, Li XX, Maitiyaer M, Huang WH, Zheng Y, Yu SL.   +9 more
europepmc   +1 more source

-engineered non-antibody protein therapeutics [PDF]

core   +1 more source

Management of autoimmune hemolytic anemia. [PDF]

Hematology Am Soc Hematol Educ Program
Barcellini W, Fattizzo B.
europepmc   +1 more source

Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy. [PDF]

Int J Mol Sci
Florea AM, Luca DG, Davidescu EI, Popescu BO.   +3 more
europepmc   +1 more source

Usefulness of Early Treatment with Efgartigimod in Patients with Generalized Myasthenia Gravis Complicated by Cardiovascular Disease: A Case Report. [PDF]

Case Rep Neurol
Kawakita R, Deguchi K.
europepmc   +1 more source

Potential drug interaction between calcitonin gene-related peptide antagonists and neonatal Fc receptor inhibitors. [PDF]

Headache
Harlan A, Weber K.
europepmc   +1 more source